GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

NCT05674422 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Patients With Locally Advanced Rectal Cancer

Interventions

DRUG: total neoadjuvant therapy

Sponsor

Grupo Espanol Multidisciplinario del Cancer Digestivo